Shanghai Junshi Biosciences (HKG:1877, SHA:688180) unit TopAlliance Biosciences recently agreed to grant LEO Pharma the exclusive right to store, distribute, promote, market, and sell toripalimab in certain regions of Europe for 12 years, a Monday bourse filing said.
The carcinoma drug will be sold by LEO Pharma in all current and future member states of the European Union, the European Economic Area, Switzerland, and the United Kingdom under the contract.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.